Roche third quarter sales slightly beat expectations with growth across divisions
Thu 06:15
Roche third quarter sales slightly beat expectations with growth across divisions ZURICH/ LONDON, Oct 22 - Roche ROPC.S sales rose in the third quarter, the Swiss drugmaker said on Thursday, slightly beating analyst expectations.
With growth in both its pharmaceuticals and diagnostics divisions, group sales came in at 16.13 billion Swiss francs ($19.61 billion), slightly above average analyst expectations of 15.75 billion Swiss francs in a company compiled consensus.
(Reporting by Patrick Wingrove and Marleen Kaesebier
Editing by Linda Pasquini)
Recent news on Roche Holding AG
See all newsNovartis presents weaker-than-expected relapse data for multiple sclerosis drug remibrutinib
Brief: Roche Says Sefaxersen Achieved Statistically Significant 43.1% Reduction In Proteinuria In Interim Phase III Data
Brief: Zymeworks Signs Exclusive Global Licensing Deal With Roche For Cancer Drug ZW209
Zymeworks licenses experimental lung cancer drug to Roche in up to $813 million deal
DB ups Roche to 'buy' on positive oncology survey